Company: DHR
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0000313616-25-000153
Chunk: 142

Company: DANAHER CORP /DE/
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 2
Chunk 142
---
 sales.

29

LIFE SCIENCES

The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies.  Additionally, the segment provides products and consumables used to filter and remove contaminants from a variety of liquids and gases in many end-market applications.

Life Sciences Selected Financial Data 

 Three-Month Period EndedSix-Month Period Ended($ in millions)June 27, 2025June 28, 2024June 27, 2025June 28, 2024Sales$1,777 $1,770 $3,457 $3,515 Operating profit (loss)(239)233 (38)468 Depreciation45 41 90 79 Amortization of intangible assets150 140 299 281 Operating profit (loss) as a % of sales(13.4)%13.2 %(1.1)%13.3 %Depreciation as a % of sales2.5 %2.3 %2.6 %2.2 %Amortization as a % of sales8.4 %7.9 %8.6 %8.0 %

Sales Growth (Decline) and Core Sales Decline

% Change Three-Month Period Ended June 27, 2025 vs. Comparable 2024 Period% Change Six-Month Period Ended June 27, 2025 vs. Comparable 2024 PeriodTotal sales growth (decline) (GAAP)0.5 %(1.5)%Impact of:Acquisitions(1.5)%(1.5)%Currency exchange rates (1.5)%(0.5)%Core sales decline (non-GAAP)(2.5)%(3.5)%

Price increases in the segment contributed 0.5% to the change in sales on a year-over-year basis during both the three and six-month periods ended June 27, 2025 and are reflected as a component of core sales above.

Total segment sales increased 0.5% and decreased 1.5% during the three and six-month periods ended June 27, 2025, respectively.